Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic studies on aminoglutethimide

H A Salhanick

    Cancer Research
    |August 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Aminoglutethimide (AG) inhibits cholesterol side-chain cleavage and aromatase enzymes by blocking cytochrome P-450s. The D-enantiomer of AG is significantly more potent than the L-enantiomer in inhibiting these steroidogenic pathways.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The isolation of progesterone from human placentae.

    Science (New York, N.Y.)·2014
    Same author

    Panel discussion: purification, structure, cDNA probes.

    Steroids·1987
    Same author

    Studies of the active site of cytochrome P-450scc with a high-affinity spin-labeled inhibitor.

    Biochemistry·1987
    Same author

    Inhibition of iron-sulfur protein-mediated reduction of cytochrome P-450SCC by specific antibodies.

    Endocrinology·1985
    Same author

    Molecular interactions of progesterone analogues with rabbit uterine cytoplasmic receptor.

    The Journal of biological chemistry·1982
    Same author

    Tamoxifen and aminoglutethimide in advanced breast cancer.

    Cancer research·1982
    Same journal

    CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

    Cancer research·2026
    Same journal

    A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

    Cancer research·2026
    Same journal

    Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

    Cancer research·2026
    Same journal

    Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

    Cancer research·2026
    Same journal

    Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

    Cancer research·2026
    Same journal

    Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

    Cancer research·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Endocrinology
    • Pharmacology

    Background:

    • Aminoglutethimide (AG) is a bicyclic compound known to inhibit key steroidogenic enzymes.
    • These enzymes, cholesterol side-chain cleavage (SCC) and aromatase, are critical for hormone synthesis and involve terminal cytochrome P-450s.

    Purpose of the Study:

    • To investigate the inhibitory mechanisms of Aminoglutethimide (AG) on cholesterol side-chain cleavage (SCC) and aromatase systems.
    • To compare the potency of the D(+) and L(-) enantiomers of AG in inhibiting these enzymatic systems.
    • To assess the in vivo effects of AG on hormone levels in animal models and humans.

    Main Methods:

    • Spectroscopic analysis to study AG's interaction with cytochrome P-450s and determine inhibition constants (Ki).
    • In vivo studies in rabbits and rats to evaluate the potency of AG enantiomers in inhibiting SCC.

    Related Experiment Videos

  • Clinical studies in women to measure the impact of AG on estrogen, progesterone, and luteinizing hormone levels.

    • Main Results:

    • AG inhibits SCC and aromatase by blocking terminal cytochrome P-450s, preventing cytochrome reduction.
    • The D(+)-AG enantiomer is 2.5 times more potent than L(-)-AG in inhibiting SCC and 40 times more potent in inhibiting aromatase.
    • In vivo studies confirmed D-AG is 5-25 times more potent than L-AG. AG administration in women led to a ~50% decrease in hormone levels.

    Conclusions:

    • Aminoglutethimide (AG) effectively inhibits steroidogenesis by targeting cytochrome P-450-dependent SCC and aromatase enzymes.
    • The D-enantiomer of AG exhibits significantly higher inhibitory potency compared to the L-enantiomer.
    • AG treatment results in substantial reductions in key hormone levels, demonstrating its efficacy in vivo.